«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:

39

期数:

2022年11期

页码:

77-81

栏目:

疾病经济负担

出版日期:

2022-10-26

文章信息/Info

Title:

Analysis of Postoperative Rehospitalization Costs and Factors Influencing Patients with Malignancy

作者:

徐庆峰¹; 潘 晔²; 武启峰¹; 刘法金¹

1.河南省人民医院，河南 郑州 450000
2.河南省中医药研究院附属医院，河南 郑州 450004

Author(s):

XU Qingfeng;  PAN Ye;  WU Qifeng;  LIU Fajin

Hennan Provincial People's Hospital, Zhengzhou Henan 450000, China

关键词:

恶性肿瘤患者; 再次住院; 住院费用; 灰色关联分析; 多元回归分析

Keywords:

patients with malignant neoplasms;  readmission;  hospitalization costs;  grey correlation analysis;  multiple regression analysis

分类号:

R19

文献标志码:

A

摘要:

目的：分析恶性肿瘤患者术后再次住院费用结构及其影响因素。方法：采用描述性统计、单因素方差分析、灰色关联分析和多元线性回归等方法，对恶性肿瘤患者术后再次住院费用进行分析。结果：恶性肿瘤患者术后再次住院费用各类别的关联系数由大到小依次是西药费、临床物理治疗费、影像学诊断费，对比2019年数据，体现医务人员技术劳务价值的医疗服务项目费用增幅明显，耗材与检查类项目费用有一定降幅；多元线性回归显示，住院费用影响因素由大到小依次为再住院天数、治疗方法、病例分型、入院病情、手术或操作次数、伴随疾病与并发症数量、性别、治疗结果、年龄。结论：压缩药品耗材费用空间，优化费用结构；规范诊治流程，提升核心病种管理能力；降本增效，助力专科运营能力提升。

Abstract:

Objective To analyze the structure of postoperative re-hospitalization costs of malignant tumor patients and its influencing factors. Methods Descriptive analysis, one-way ANOVA analysis, grey correlation analysis and multiple linear regression were used to analyze the postoperative re-hospitalization costs of malignant tumor patients. Results The correlation coefficients of each category of post-operative re-hospitalization costs for malignant tumour patients were, in descending order, the costs of western medicine, clinical physiotherapy and diagnostic imaging. Comparing the 2019 data, the costs of medical service items reflected the value of technical labour of medical personnel increased significantly, while the costs of consumables and examination items decreased to a certain extent. The multiple linear regression showed that the factors influencing the cost of hospitalisation were, in descending order, the number of days of readmission, treatment method, case type, admission condition, number of surgeries or operations, number of concomitant diseases and complications, gender, treatment outcome, and age. Conclusion It is necessary to compress the cost space of drugs and consumables to optimize the cost structure, standardize the consultation and treatment process to improve the management capacity of core diseases, and reduce costs and increase efficiency to help improve the operational capacity of specialties.

常用功能

更新日期/Last Update: 2022-10-26